Furthermore, the majority of advances in genetics—so often a guiding hand for neurodegenerative research in the identification of therapeutic targets—have occurred only relatively recently in FTD (Hutton et al., 1998; Watts et al., 2004; Baker et al., 2006; Cruts et al., 2006; Sreedharan et al., 2008; DeJesus-Hernandez et al., 2011; Renton et al., 2011), and have uncovered genes such as progranulin (GRN) and Tar DNA binding protein (TARDBP) with little preexisting neurological literature. Here, GRN is linked to frontotemporal dementia.